All In Biotech

Drug Trial Radar · NCT07886476

IBI3034 Study in Healthy Adults and Patients With Primary IgA Nephropathy

A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of IBI3034 Following Single Ascending Dose in Healthy Adults and Multiple Ascending Doses in Participants With Primary IgA Nephropathy

Last checked: Nov 20, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 100 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

100

Planned (sponsor's estimate)

Start

Oct 15, 2026

Primary completion

Jan 31, 2027

Study completion Feb 28, 2028

Sponsor

Sponsor type
Industry
First posted
Oct 21, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Part 1 is a Single Ascending Dose (SAD) study, and Part 2 is a Multiple Ascending Dose (MAD) study

Conditions

  • IgA Nephropathy (IgAN)

Interventions

  • IBI3034Drug

    IBI3034,SC/IV,corresponding dose regimen according to study design

  • PlaceboDrug

    Matching placebo of IBI3034,SC/ IV ,corresponding dose regimen according to study design

  • TelitaciceptDrug

    Telitacicept 240 mg SC QW × 24 doses (Weeks 0-24).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety: Incidence of adverse events (AEs) and serious adverse events (SAEs) following a single dose of IBI3034 in healthy participants(Part 1)Time frame: through study completion,an average of 169 days
  2. Safety: Incidence of AEs and SAEs following multiple doses of IBI3034 in participants with primary IgA nephropathy(Part 2)Time frame: through study completion,an average of 252 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Peking University First Hospital

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.